Table 1.
Included patients baseline demographics and clinical and sequenced sample characteristics.
| Patient Characteristics | Mild Outcome | Severe Outcome | ||
|---|---|---|---|---|
| Baseline Demographics | Number of patients (% of total) | 97 (55%) | 79 (45%) | |
| Age in median years (range) | 34 (0–91) | 73 (1–97) | ||
| Sex | Male | 48 | 36 | |
| Female | 48 | 43 | ||
| Origin | Lyon University Hospitals | 6 | 65 | |
| Surveillance network | 91 | 14 | ||
| Sample Characteristics | Sample type | NPA | 2 | 6 |
| NS | 95 | 49 | ||
| TBA | 0 | 13 | ||
| BAL | 0 | 11 | ||
| Median time since onset of symptoms, days (range) | 1 (0–5) | 3 (0–8) | ||
| Viral load—median cycle threshold (range) | 19.7 (14.9–30) | 23.3 (17–35.3) | ||
| Clinical Characteristics | Vaccinated against Influenza for the current season | 21 | 7 | |
| Severe outcome risk factor * | 17 | 65 | ||
| Main severity component | Respiratory | - | 70 | |
| Neurological | 5 | |||
| Multiple organ failure | 4 | |||
* Risk factors included age >65 years, immunodeficiency, ongoing cancer, chronical pulmonary, cardio-vascular, or neuro-muscular disease, BMI >35, diabetes, and ongoing pregnancy. NPA: Nasopharyngeal aspirate; NS: Nasal swab; TBA: Tracheobronchial aspirate; BAL: Bronchoalveolar Lavage.